What is Mounjaro (Tirzepatide)?
Mounjaro (tirzepatide) is a breakthrough weekly injectable medication developed by Eli Lilly. It is the first and only FDA-approved dual GIP and GLP-1 receptor agonist, meaning it activates two separate gut-hormone pathways simultaneously — making it significantly more powerful than single-action GLP-1 drugs like Ozempic.
In landmark clinical trials (SURMOUNT programme), patients on Mounjaro lost an average of 20–22% of their body weight over 72 weeks — the highest weight reduction ever recorded in a pharmaceutical trial. At DermaTales, we administer Mounjaro under strict physician supervision, with full monitoring and personalised dose titration for optimal safety and results.
How Mounjaro Works
Unlike traditional weight loss medications, Mounjaro operates via two complementary mechanisms that together produce far greater outcomes:
GLP-1 Receptor Activation
Reduces appetite, slows gastric emptying, and lowers blood sugar by stimulating insulin release in a glucose-dependent manner — preventing dangerous hypoglycaemia.
GIP Receptor Activation
Enhances fat metabolism directly in fat cells, reduces inflammatory signals, and amplifies the appetite-suppressing effects of GLP-1 — uniquely Mounjaro's advantage.
Visceral Fat Reduction
Clinical data confirms Mounjaro specifically reduces visceral (abdominal) fat — the most dangerous type linked to cardiovascular disease and metabolic syndrome.
Cardiometabolic Benefits
Significant improvements in blood pressure, cholesterol, HbA1c, and liver fat seen in trials — making Mounjaro uniquely beneficial for those with diabetes or metabolic syndrome.
Ideal Candidates
- Adults with BMI ≥ 30, or ≥ 27 with a weight-related health condition.
- People with Type 2 diabetes seeking simultaneous glucose and weight control.
- Those who haven't achieved sufficient results with Ozempic or other GLP-1 drugs.
- Patients with metabolic syndrome, PCOS, or high cardiovascular risk.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pregnancy or planned pregnancy — must be stopped ≥2 months before conception.
- Active or prior pancreatitis (relative contraindication, assessed case-by-case).
Mounjaro Treatment Protocol at DermaTales
Pre-Treatment Medical Screening
Full history, physical examination, and blood panel (thyroid, pancreatic enzymes, blood sugar, lipids, kidneys, liver) to confirm eligibility and establish a baseline.
Starting Dose: 2.5 mg Weekly
Mounjaro is always initiated at the lowest dose (2.5 mg SC weekly) for 4 weeks to allow your body to adapt and minimise gastrointestinal side effects.
Gradual Dose Escalation
Doses are increased every 4 weeks (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) based on tolerance and clinical response, up to the therapeutic target dose.
Monthly Follow-Up & Monitoring
Regular clinic visits to monitor weight, body composition, blood markers, and side effects, with dietary and lifestyle coaching at every visit.
Maintenance & Transition Planning
After reaching goal weight, a structured weaning or long-term maintenance protocol is designed to preserve your results and support physiological adaptation.
Why Get Mounjaro at DermaTales?
Physician-Only Prescribing
Mounjaro is a prescription-only medication. At DermaTales, it is prescribed exclusively by qualified doctors following a full clinical assessment — never dispensed without consultation.
Authentic, Verified Medication
We source Mounjaro only from authorised pharmaceutical distributors — guaranteeing product authenticity, cold-chain integrity, and correct storage at all times.
Integrated Weight Loss Support
Medication is combined with personalised nutrition planning, body composition tracking, and lifestyle coaching for results that go far beyond what the drug alone can achieve.
Safe Injection Administration
While Mounjaro is a self-injectable pen, our team provides full training, and in-clinic administration is available for patients who prefer it.
Frequently Asked Questions
Need immediate help?
WhatsApp Us